DSpace Repository

Andrographis paniculata - A multicentric, randomized, double-blind homoeopathic pathogenetic trial

Show simple item record

dc.contributor.author Rajpal
dc.contributor.author Singh, Vinay Kr.
dc.contributor.author Dutta, B.N.
dc.contributor.author Das, S.
dc.contributor.author Mal, P.C.
dc.contributor.author Bhakat, A.K.
dc.contributor.author Roy, R.K.
dc.contributor.author Chaudhary, C.P.
dc.date.accessioned 2019-04-03T11:20:11Z
dc.date.available 2019-04-03T11:20:11Z
dc.date.issued 2011
dc.identifier.citation Indian Journal of Research In Homoeopathy Vol.5 (2) en_US
dc.identifier.uri http://aohindia.in:8080/xmlui/handle/123456789/1338
dc.description.abstract Objective: To elicit the pathogenetic response of the drug Andrographis paniculata in homoeopathic potencies on healthy human beings. Methodology: Drug Andrographis paniculata was proved by the Central Council for Research in Homoeopathy through double-blind, randomized, placebo-controlled method. The study was conducted at three centers. The drug was proved in two potencies (6C and 30C) on 39 apparently healthy volunteers who were selected after conducting pre-trial medical examination by the medical specialists and routine laboratory investigations. In the first phase volunteers were given 56 doses (04 doses per day for 14 days) of placebo. In the next two phases 56 doses (04 doses per day for 14 days) of each potency or placebo were consumed. The symptoms generated during the trial period were noted by the volunteers and elaborated by the Proving Masters. The data obtained from all the three centers was compiled at proving-cum-data processing cell at CCRH headquarters after de-coding. Observations: Out of the 23 provers who were on actual drug trial, 06 manifested symptoms. Drug was able to produce symptoms in both the potencies more or less related to every part of the body. Some of the symptoms have been reproved which are mentioned in different literatures after the fragmentary proving. Conclusion: New and reproved pathogenetic responses elicited during the proving trial expands the scope of use of the drug Andrographis paniculata and will benefit the research scholars and clinicians. These symptoms will carry more value when verified clinically. en_US
dc.description.sponsorship CCRH en_US
dc.language.iso en en_US
dc.subject pathogenetic effect en_US
dc.subject homoeopathic pathogenetic trial en_US
dc.subject drug proving en_US
dc.subject Andrographis paniculata en_US
dc.title Andrographis paniculata - A multicentric, randomized, double-blind homoeopathic pathogenetic trial en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account